Evidence map›Paper›PMID 26258847›Full record

ArticleNature genetics2015

Genomic analysis of mycosis fungoides and Sézary syndrome identifies recurrent alterations in TNFR2.

Alexander Ungewickell, Aparna Bhaduri, Eon Rios, Jason Reuter, Carolyn S Lee, Angela Mah, Ashley Zehnder, Robert Ohgami, Shashikant Kulkarni, Randall Armstrong and 7 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature genetics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 154 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
154citing papers in PubMed, 3 pooled it
29.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

154 citing papers in PubMed, 3 syntheses or guidelines pooled it, 273 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sézary Syndrome: A Multicenter Phase II Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020
    Trial
  8. Trial
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

94 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 5 institutions in 1 country.

Alexander UngewickellProgram in Epithelial Biology, Stanford University, Stanford, California, USA.
Aparna BhaduriProgram in Epithelial Biology, Stanford University, Stanford, California, USA.
Eon RiosProgram in Epithelial Biology, Stanford University, Stanford, California, USA.
Jason ReuterDepartment of Genetics, Stanford University, Stanford, California, USA.
Carolyn S LeeProgram in Epithelial Biology, Stanford University, Stanford, California, USA.
Angela MahProgram in Epithelial Biology, Stanford University, Stanford, California, USA.
Ashley ZehnderProgram in Epithelial Biology, Stanford University, Stanford, California, USA.
Robert OhgamiDepartment of Pathology, Stanford University, Stanford, California, USA.
Shashikant KulkarniDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri, USA.ORCID http://orcid.org/0000-0002-9349-0787
Randall ArmstrongDivision of Blood and Marrow Transplantation, Stanford University, Stanford, California, USA.
Wen-Kai WengDivision of Blood and Marrow Transplantation, Stanford University, Stanford, California, USA.
Dita GratzingerDepartment of Pathology, Stanford University, Stanford, California, USA.
Mahkam TavallaeeMultidisciplinary Cutaneous Lymphoma Program, Stanford University, Stanford, California, USA.ORCID http://orcid.org/0000-0002-3543-7259
Alain RookDepartment of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Michael SnyderDepartment of Genetics, Stanford University, Stanford, California, USA.
Youn KimMultidisciplinary Cutaneous Lymphoma Program, Stanford University, Stanford, California, USA.
Paul A KhavariProgram in Epithelial Biology, Stanford University, Stanford, California, USA.
Stanford University · USStanford Blood Center · USUniversity of Pennsylvania · USVA Palo Alto Health Care System · USWashington University in St. Louis · US

Funding

Leveraging innovative technologies in basic and clinical cancer researchT32CA009302 · NCI · STANFORD UNIVERSITY · PI LAURA D ATTARDI, Aaron M Newman · 1985 to 2026
$19.1M
Regulators of TumorigenesisR01CA142635 · NCI · STANFORD UNIVERSITY · PI KHAVARI, PAUL · 2011 to 2020
$3.5M
SMRT-2 in Epidermal NeoplasiaF31CA180408 · NCI · STANFORD UNIVERSITY · PI BHADURI, APARNA · 2013 to 2014
$85k
The role of beta integrins in epidermal tumor progressionF32CA168091 · NCI · STANFORD UNIVERSITY · PI UNGEWICKELL, ALEXANDER · 2012 to 2014
$82k
NCI NIH HHS F31 CA180408NCI NIH HHS F32 CA168091NCI NIH HHS R01 CA142635NCI NIH HHS R01CA142635NCI NIH HHS T32 CA009302
6 · The paper itself

Abstract

Mycosis fungoides and Sézary syndrome comprise the majority of cutaneous T cell lymphomas (CTCLs), disorders notable for their clinical heterogeneity that can present in skin or peripheral blood. Effective treatment options for CTCL are limited, and the genetic basis of these T cell lymphomas remains incompletely characterized. Here we report recurrent point mutations and genomic gains of TNFRSF1B, encoding the tumor necrosis factor receptor TNFR2, in 18% of patients with mycosis fungoides and Sézary syndrome. Expression of the recurrent TNFR2 Thr377Ile mutant in T cells leads to enhanced non-canonical NF-κB signaling that is sensitive to the proteasome inhibitor bortezomib. Using an integrative genomic approach, we additionally discovered a recurrent CTLA4-CD28 fusion, as well as mutations in downstream signaling mediators of these receptors.

Indexed as

Antineoplastic AgentsBase SequenceBortezomibCD28 AntigensCell Line, TumorCTLA-4 AntigenDNA Mutational AnalysisDrug Resistance, NeoplasmGene ExpressionGene Expression Regulation, NeoplasticGenetic Predisposition to DiseaseGenome-Wide Association StudyGenomicsHumansMycosis FungoidesOncogene Proteins, FusionAntineoplastic AgentsBortezomibCD28 AntigensCTLA-4 AntigenCTLA4 protein, humanOncogene Proteins, FusionReceptors, Tumor Necrosis Factor, Type II

Identifiers

PMID26258847
PMCPMC6091217
OpenAlexW2202793491

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.